EchoSolv AS vs ClearRead CT
AI Verdict
Choose EchoSolv AS if…
Choose EchoSolv AS if your primary need is highly accurate and efficient AI-powered clinical decision support specifically for identifying patients at risk for severe aortic stenosis from echocardiogram measurements. This tool is ideal for cardiology departments looking to integrate an ultra-fast, measurement-based AI solution into existing PACS workflows without requiring EMR integration, providing consistent probability assessments and guideline checks.
View EchoSolv AS →Choose ClearRead CT if…
Choose ClearRead CT if your focus is on enhancing the detection and analysis of pulmonary nodules and coronary artery calcification within CT scans across a broader cardiothoracic scope. This AI suite is best suited for radiology and pulmonology departments aiming to improve diagnostic accuracy, reduce reading times, and streamline workflows through advanced vessel suppression and automated nodule tracking and characterization.
View ClearRead CT →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | EchoSolv AS | ClearRead CT |
|---|---|---|
| Pricing | Unknown | Contact for pricing |
| Deployment | Cloud-based | On-premise (stand-alone server, virtual machine) and Cloud |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
EchoSolv ASEchoSolv AS emphasizes ultra-fast risk detection, completing analysis in under 3 seconds. Its measurement-based AI, which analyzes numerical data rather than images and requires no EMR integration, suggests a simpler and less intrusive integration into existing workflows. ClearRead CT also streamlines workflows and reduces reading time, but EchoSolv AS's specific speed and data input method offer a slight edge in ease of use and integration.
Clinical Value
EchoSolv ASBoth tools are FDA-cleared and demonstrate strong clinical utility. However, EchoSolv AS provides highly specific and impressive quantifiable clinical outcomes, including near-perfect accuracy (AUC of 0.986) in detecting severe aortic stenosis, 82.2% sensitivity, and 98.1% specificity. It also notably improved gender equity in diagnosis for AS. ClearRead CT's 29% reduction in missed actionable nodules is significant, but EchoSolv AS's detailed metrics and impact on diagnostic equity give it a stronger clinical value proposition.
Pricing & Value
EchoSolv ASEchoSolv AS offers greater transparency regarding its financial value proposition by identifying an existing reimbursement code (93799) with an estimated fee-per-use rate of US$100 to US$150 for users. This provides a clear pathway for institutions to understand the financial benefits of adoption. ClearRead CT, in contrast, only states 'contact for pricing' and does not publicly detail its reimbursement model or pricing structure for institutional use.
Enterprise Readiness
ClearRead CTClearRead CT demonstrates superior enterprise readiness by offering both on-premise and cloud deployment options, providing greater flexibility for diverse IT infrastructures. Its extensive deployment across 22 VA hub locations and 87 spoke sites nationwide highlights its proven scalability and adoption within large healthcare systems. While EchoSolv AS explicitly states HIPAA compliance and BAA availability, ClearRead CT's deployment flexibility and large-scale government adoption are more indicative of robust enterprise readiness.
Innovation
ClearRead CTClearRead CT features a patented 'Vessel Suppression (Clear Visual Intelligence)' technology that directly enhances image interpretation by removing obscuring anatomical structures. This distinct technological innovation leads to improved clarity and diagnostic accuracy for pulmonary nodules. While EchoSolv AS's measurement-based AI and avoidance of LVOT measurements are innovative, ClearRead CT's vessel suppression is a more unique and impactful advancement in imaging AI.
Support & Docs
ClearRead CTClearRead CT provides a significantly more comprehensive and publicly detailed support structure, including direct customer care contact information (email, phone, hours), FAQs, system requirements, workflows, and readily available user manuals. It also offers 'Customer Success Live' webinars and a rich resource library. EchoSolv AS mentions 'Feedback & Support' and a 'dedicated team,' but lacks the specific, detailed offerings of ClearRead CT.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | EchoSolv AS | ClearRead CT |
|---|---|---|
| Name | EchoSolv AS | ClearRead CT |
| Company | Echo IQ | RIVERAIN TECHNOLOGIES |
| Primary Clinical Focus | Identify patients at risk for severe aortic stenosis from echocardiograms | Enhancing pulmonary nodule detection and coronary artery calcification analysis in CT scans |
| Analyzed Data/Modality | Echocardiogram measurements (numerical measurements, not images) | CT scans |
| Key AI Functionality | AI-powered clinical decision support for severe aortic stenosis probability, guideline check, second reader support, ultra-fast risk detection | Pulmonary Nodule Detection, Patented Vessel Suppression, Nodule Characterization and Measurement, Automated Nodule Tracking, Coronary Artery Calcification (CAC) Scoring |
| Specialties Supported | Cardiology, Cardiothoracic Surgery | Cardiology, Pulmonology, Radiology |
Videos
Demos, reviews, and walkthroughs featuring EchoSolv AS and ClearRead CT.